Mismatch repair protein expression by IHC
Детермінований перегляд YAML-сутності з джерельної бази. Клінічний авторитет лишається за вказаними source ID та статусом клінічного sign-off.
| ID | BIO-DMMR-IHC |
|---|---|
| Тип | Біомаркер |
| Синоніми | MLH1/MSH2/MSH6/PMS2 panelMMR IHCdMMR / pMMR by IHCЕкспресія MMR-білків (ІГХ) |
| Статус | переглянуто 2026-04-26 |
| Хвороби | Не вказано |
| Джерела | SRC-NCCN-COLON-2025 |
Дані про біомаркер
| Тип біомаркера | protein_expression_ihc |
|---|---|
| Вимірювання | MethodIHC for MLH1, MSH2, MSH6, PMS2 on FFPE; loss of any → dMMR Unitscategorical: dMMR (≥1 protein lost) | pMMR (all retained) Roundingcategorical |
| Пов’язані біомаркери | BIO-MSI-STATUS |
Де використовується
Indications
IND-ENDOMETRIAL-2L-DOSTARLIMAB-DMMR- IND-ENDOMETRIAL-2L-DOSTARLIMAB-DMMRIND-ENDOMETRIAL-2L-PEMBRO-LENVA-PMMR- IND-ENDOMETRIAL-2L-PEMBRO-LENVA-PMMRIND-ENDOMETRIAL-ADVANCED-1L-DOSTARLIMAB-CHEMO- IND-ENDOMETRIAL-ADVANCED-1L-DOSTARLIMAB-CHEMO
Questionnaires
QUEST-ENDOMETRIAL-1L-STUB- Endometrial carcinoma — first line
Біомаркер
BIO-LYNCH-PANEL-SPLIT- Lynch syndrome germline panel — gene-resolved (MLH1 / MSH2 / MSH6 / PMS2 / EPCAM)BIO-MSI-STATUS- Microsatellite instability statusBIO-POLD1-HYPERMUTATOR- POLD1 hypermutator phenotype (proofreading-domain mutation)BIO-POLE-HYPERMUTATOR- POLE hypermutator phenotype (proofreading-domain mutation)BIO-TMB-HIGH- Tumor mutational burden (TMB-high)BIO-TP53-IHC- TP53 IHC (aberrant p53 expression pattern)
Клінічна застосовність
BMA-EPCAM-GERMLINE-CRC- EPCAM germline deletion (3' end) silences downstream MSH2 by promoter hypermethylation →...BMA-EPCAM-GERMLINE-ENDOMETRIAL- EPCAM germline deletion silences MSH2 → Lynch syndrome with dMMR endometrial cancer pheno...BMA-MLH1-GERMLINE-CRC- MLH1 germline loss-of-function in crc produces dMMR/MSI-H phenotype. Pan-tumor MSI-H ICI...BMA-MLH1-GERMLINE-ENDOMETRIAL- MLH1 germline loss-of-function in endometrial produces dMMR/MSI-H phenotype. Pan-tumor MS...BMA-MLH1-GERMLINE-GASTRIC- MLH1 germline loss-of-function in gastric produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MLH1-GERMLINE-OVARIAN- MLH1 germline loss-of-function in ovarian produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MLH1-GERMLINE-PROSTATE- MLH1 germline loss-of-function in prostate produces dMMR/MSI-H phenotype. Pan- tumor MSI-...BMA-MLH1-GERMLINE-UROTHELIAL- MLH1 germline loss-of-function in urothelial produces dMMR/MSI-H phenotype. Pan-tumor MSI...BMA-MLH1-SOMATIC-CRC- MLH1 somatic loss-of-function in crc produces dMMR/MSI-H phenotype. Pan-tumor MSI-H ICI e...BMA-MLH1-SOMATIC-ENDOMETRIAL- MLH1 somatic loss-of-function in endometrial produces dMMR/MSI-H phenotype. Pan-tumor MSI...BMA-MLH1-SOMATIC-GASTRIC- MLH1 somatic loss-of-function in gastric produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MLH1-SOMATIC-OVARIAN- MLH1 somatic loss-of-function in ovarian produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MLH1-SOMATIC-PROSTATE- MLH1 somatic loss-of-function in prostate produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MLH1-SOMATIC-UROTHELIAL- MLH1 somatic loss-of-function in urothelial produces dMMR/MSI-H phenotype. Pan-tumor MSI-...BMA-MSH2-GERMLINE-CRC- MSH2 germline loss-of-function in crc produces dMMR/MSI-H phenotype. Pan-tumor MSI-H ICI...BMA-MSH2-GERMLINE-ENDOMETRIAL- MSH2 germline loss-of-function in endometrial produces dMMR/MSI-H phenotype. Pan-tumor MS...BMA-MSH2-GERMLINE-GASTRIC- MSH2 germline loss-of-function in gastric produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MSH2-GERMLINE-OVARIAN- MSH2 germline loss-of-function in ovarian produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MSH2-GERMLINE-PROSTATE- MSH2 germline loss-of-function in prostate produces dMMR/MSI-H phenotype. Pan- tumor MSI-...BMA-MSH2-GERMLINE-UROTHELIAL- MSH2 germline loss-of-function in urothelial produces dMMR/MSI-H phenotype. Pan-tumor MSI...BMA-MSH2-SOMATIC-CRC- MSH2 somatic loss-of-function in crc produces dMMR/MSI-H phenotype. Pan-tumor MSI-H ICI e...BMA-MSH2-SOMATIC-ENDOMETRIAL- MSH2 somatic loss-of-function in endometrial produces dMMR/MSI-H phenotype. Pan-tumor MSI...BMA-MSH2-SOMATIC-GASTRIC- MSH2 somatic loss-of-function in gastric produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MSH2-SOMATIC-OVARIAN- MSH2 somatic loss-of-function in ovarian produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MSH2-SOMATIC-PROSTATE- MSH2 somatic loss-of-function in prostate produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MSH2-SOMATIC-UROTHELIAL- MSH2 somatic loss-of-function in urothelial produces dMMR/MSI-H phenotype. Pan-tumor MSI-...BMA-MSH6-GERMLINE-CRC- MSH6 germline loss-of-function in crc produces dMMR/MSI-H phenotype. Pan-tumor MSI-H ICI...BMA-MSH6-GERMLINE-ENDOMETRIAL- MSH6 germline loss-of-function in endometrial produces dMMR/MSI-H phenotype. Pan-tumor MS...BMA-MSH6-GERMLINE-GASTRIC- MSH6 germline loss-of-function in gastric produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MSH6-GERMLINE-OVARIAN- MSH6 germline loss-of-function in ovarian produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MSH6-GERMLINE-PROSTATE- MSH6 germline loss-of-function in prostate produces dMMR/MSI-H phenotype. Pan- tumor MSI-...BMA-MSH6-GERMLINE-UROTHELIAL- MSH6 germline loss-of-function in urothelial produces dMMR/MSI-H phenotype. Pan-tumor MSI...BMA-MSH6-SOMATIC-CRC- MSH6 somatic loss-of-function in crc produces dMMR/MSI-H phenotype. Pan-tumor MSI-H ICI e...BMA-MSH6-SOMATIC-ENDOMETRIAL- MSH6 somatic loss-of-function in endometrial produces dMMR/MSI-H phenotype. Pan-tumor MSI...BMA-MSH6-SOMATIC-GASTRIC- MSH6 somatic loss-of-function in gastric produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MSH6-SOMATIC-OVARIAN- MSH6 somatic loss-of-function in ovarian produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MSH6-SOMATIC-PROSTATE- MSH6 somatic loss-of-function in prostate produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MSH6-SOMATIC-UROTHELIAL- MSH6 somatic loss-of-function in urothelial produces dMMR/MSI-H phenotype. Pan-tumor MSI-...BMA-MSI-STATUS-CRC- MSI-H (microsatellite instability-high) CRC is the primary biomarker for first-line pembr...BMA-MSI-STATUS-ENDOMETRIAL- MSI-H/dMMR endometrial cancer (~25-30% of advanced cases) qualifies for ICI-based regimen...- ... 12 ще
Тривожна ознака
RF-ENDOMETRIAL-HIGH-RISK-BIOLOGY- dMMR/MSI-high OR p53-abnormal OR POLE-mutated — TCGA classification drives ICI eligibilit...